Assessment of Quality of Life in Chronic Otitis Media Patients Undergoing Type I Tympanoplasty

慢性中耳炎患者接受 I 型鼓室成形术后的生活质量评估

阅读:1

Abstract

INTRODUCTION: Chronic otitis media (COM) contributes to considerable morbidity, with hearing loss and tympanic membrane perforations negatively affecting quality of life (QOL). This study aims to assess the outcomes following tympanoplasty in patients with unilateral mucosal COM, with a focus on health-related quality of life (HR-QOL) using the Chronic Otitis Media Outcome Test 15 (COMOT-15) questionnaire, in addition to evaluating audiological and surgical results. METHODOLOGY: A prospective study of 70 patients undergoing Type I tympanoplasty was conducted from April 2023 to July 2024 in a tertiary care hospital in Delhi. Pre- and postoperative assessments included pure-tone audiometry (PTA) and COMOT-15 surveys. Graft uptake, hearing thresholds, and HR-QOL domains (symptoms, mental health, social function) were analyzed using paired t-tests and chi-square tests (IBM SPSS Statistics for Windows, Version 27 (Released 2020; IBM Corp., Armonk, New York)). RESULTS: Postoperatively, 85.7% achieved normal hearing (vs. 0% preoperatively; p = 0.001), with the mean air-bone gap improving from 28.85 ± 7.99 dB to 12.42 ± 7.26 dB (p = 0.001). Graft uptake was successful in 94.3%. COMOT-15 scores declined significantly (31.61 to 7.18; p = 0.001), with 85.7% reporting no QOL issues. Severe ear discharge reduced from 37.1% to 4.3% (p = 0.001), and psychological scores improved from 11.92 ± 1.67 to 0.77 ± 2.49 (p = 0.001). Hearing restoration was associated with mental health improvement (90.9% marked improvement; p < 0.001). CONCLUSION: Type I tympanoplasty significantly restores hearing and HR-QOL in COM patients. The COMOT-15 tool effectively quantifies subjective benefits, highlighting the procedure's dual clinical and psychosocial impact.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。